Issue of Equity

Akers Biosciences, Inc.

(the "Company")

Issue of Equity

Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), a leading designer and manufacturer of rapid diagnostic screening and testing products, notes that, further to this morning's announcement, application has been made for the 190,000 Common Shares of no par value ("Common Shares") to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place on January 15, 2015.

The new Common Shares will rank pari passu with the existing shares of the Company. Subsequent to Admission, the total number of issued Common Shares will be 5,203,352. There are no Common Shares held in treasury and so the total number of voting rights in the Company will be 5,203,352.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For more information:

Akers Biosciences, Inc.

Raymond F. Akers, Jr. PhD

Executive Chairman of the Board

Tel. +1 856 848 8698

RedChip Companies, Inc. (US Investor Relations)

Jon Cunningham

Tel. +1 407 644 4256 x107

finnCap (UK Nominated Adviser and Broker)

Geoff Nash / Scott Mathieson (Corporate Finance)

Steve Norcross (Broking)

Tel: +44 (0)20 7220 0500

Vigo Communications (UK Investor Relations)

Ben Simons / Alexandra Roper

Tel. +44 (0)20 7016 9570

Email. [email protected]